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uncommonly wellTom C. Nguyen, MDSee related article on pages 2720-6.When you can do the common things of life in an un-
common way, you will command the attention of the
world.
George Washington Carver
More than a century ago, the renowned British surgeon
Stephen Paget stated, ‘‘No new method and no new
discovery can overcome the natural difficulties that attend a
wound of the heart.’’1 This statement, however, has since
been refuted by the many advances in cardiac surgery. Today,
coronary artery bypass grafting (CABG) remains one of the
most common operations performed by cardiac surgeons,
withmore than 300,000 procedures in theUnited States annu-
ally.2 Since the procedure’s introduction, advances in CABG
technique haveminimized complications and adverse events.
Even though the procedure is both common and
relatively low risk, the need for updating our literature
with novel insights is mandatory for maintaining the highest
possible level of patient care. As one of the most studied
procedures in modern scientific literature, CABG outcomes
need to be well reviewed and continuously audited. The
analysis performed by Weisel and colleagues3 is much
needed and represents a new reading into the perioperative
management of the CABG procedure.
The study of Weisel and colleagues3 uses data from the
trial Reduction in Cardiovascular Events by AcaDesine in
Subjects Undergoing CABG (RED-CABG),4 one of the
largest multicenter, randomized, double-blinded, placebo-
controlled studies to assess cardiac events after nonemer-
gencyCABGformoderate- tohigh-riskpatients. Theprimary
efficacy end point of the study was a composite of death from
any cause, nonfatal stroke, and severe left ventricular
dysfunction requiring mechanical support within 28 days.
Through the use of logistic regression modeling, the re-
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tive risk factors, a history of heart failure, increasing age, a
history of peripheral vascular disease, and taking aspirin
beforeCABG(whichhad a protective effect), and1 intraoper-
ative variable, the duration of cardiopulmonary bypass.
Weisel and colleagues3 are to be commended for their
analysis. Perhaps the most notable finding was that a history
of heart failure independently contributed more to adverse
outcomes than did a low ejection fraction, suggesting that
patients who have heart failure but preserved systolic
function warrant increased attention when undergoing
CABG. Although heart failure is recognized as an inherent
risk factor, the relative contribution of heart failure versus
ejection fraction to CABG outcomes has not been well
studied. This finding thus could serve to create an important
paradigm shift as we strive for better risk stratification of
patients before CABG.
Although this effect has previously been reported, this
study also emphasized the importance of preoperative aspirin.
The composite outcome rate among patients taking preoper-
ative aspirin was half that of those who were not (4.58% vs
8.72%). The benefits of preoperative and early postoperative
administration of aspirin have been well documented, and
this study further underscores aspirin’s value. As it stands,
preoperative aspirin is a class I indication according to the
2011 American College of Cardiology and American Heart
Association’ guideline for CABG. It is not, however, a Soci-
ety of Thoracic Surgeons quality performance measure.5 The
results from this study suggest that perhaps it should be.
One notable limitation of the analysis was the narrow
primary efficacy end points for the trial. It is unclear why
other highly prevalent morbidities also associated with post-
operative outcomes in CABG, such as renal failure, were not
considered. This seems especially relevant to the high-risk
group of patients included in the RED-CABG trial. Weisel
and colleagues3 state that patients with preoperative renal
dysfunctionwere excluded to avoid complications associated
with acadesine treatment; however, this limitation should be
considered when extrapolating these findings to the high-risk
CABG population, which has a high prevalence of renal
dysfunction.
An additional limitation relates to study design. The
original study was designed to test the impact of acadesine
on outcomes after CABG, and the limitations in using such
a study to identify general predictors of outcome after
CABG are substantial. For example, the original trial sought
to determine the effect of acadesine rather than to evaluate
predictors of outcome.diovascular Surgery c Volume 148, Number 6 2727
Editorial Commentary NguyenDespite these limitations, Weisel and colleagues3 are to be
congratulated on their contribution. Although CABG
is common, its widespread use necessitates the
continuous evaluation of outcomes to maintain the highest
level of patient care. As George Washington Carver
notes, ‘‘When you can do the common things of life in an un-
commonway, you will command the attention of theworld.’’
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